SLS (STOCKS)
SELLAS Life Sciences Group, Inc. Common Stock
$3.670000
-0.090000 (-2.39%)
Prev close: $3.760000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Angelos M. Stergiou
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $524.81M
- Employees
- 15
- P/E (TTM)
- -13.11
- P/B (TTM)
- 10.31
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.06 | $-0.07 | +0.0067 | +10.05% |
|
Jun 2025 (Q2)
|
$-0.07 | $-0.08 | +0.0132 | +15.87% |
|
Mar 2025 (Q1)
|
$-0.07 | $-0.11 | +0.0361 | +34.02% |
|
Dec 2024 (Q4)
|
$-0.08 | $-0.11 | +0.0284 | +26.20% |
Financial Statements
| Revenues | $0.00 |
| Cost Of Revenue | $0.00 |
| Costs And Expenses | $26.94M |
| Nonoperating Income/Loss | $995.00K |
| Selling, General, and Administrative Expenses | $11.21M |
| Operating Income/Loss | -$26.94M |
| Income/Loss From Continuing Operations After Tax | -$25.94M |
| Income/Loss From Continuing Operations Before Tax | -$26.31M |
| Net Income/Loss | -$25.94M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$25.94M |
| Net Income/Loss Available To Common Stockholders, Basic | -$25.94M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.28 |
| Diluted Earnings Per Share | -$0.28 |
| Basic Average Shares | 102,575,765 |
| Diluted Average Shares | 298,976,942 |
| Assets | $51.56M |
| Current Assets | $49.05M |
| Noncurrent Assets | $2.50M |
| Liabilities | $5.93M |
| Current Liabilities | $5.93M |
| Accounts Payable | $2.31M |
| Wages | $1.42M |
| Other Current Liabilities | $2.20M |
| Noncurrent Liabilities | $0.00 |
| Equity | $45.63M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $45.63M |
| Liabilities And Equity | $51.56M |
| Net Cash Flow From Operating Activities | -$30.62M |
| Net Cash Flow From Operating Activities, Continuing | -$30.62M |
| Net Cash Flow From Investing Activities | -$23.29M |
| Net Cash Flow From Investing Activities, Continuing | -$23.29M |
| Net Cash Flow From Financing Activities | $53.91M |
| Net Cash Flow From Financing Activities, Continuing | $53.91M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$25.94M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$25.94M |
| Other Comprehensive Income/Loss | $0.00 |